SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Tofogliflozin, an SGLT2 inhibitor, demonstrates excellent tolerability and significantly reduces the magnetic resonance imaging proton density fat fraction (MRI-PDFF) in patients with NAFLD and T2DM [199].